Houston data science company expands pandemic-inspired research tool

by the numbers

Mercury Data Science has taken a tool it originally developed for COVID-19 research and applied it into new areas of research and innovation. Photo via Getty Images

Last fall, Houston-based Mercury Data Science released an AI-driven app designed to help researchers unlock COVID-19-related information tucked into biomedical literature. The app simplified access to data about subjects like genes, proteins, drugs, and diseases.

Now, a year into the coronavirus pandemic, Mercury Data Science is applying this technology to areas like agricultural biotech, cancer therapeutics, and neuroscience. It's an innovation that arose from the pandemic but that promises broader, long-lasting benefits.

Angela Holmes, chief operating officer of Mercury Data Science, says the platform relies on an AI concept known as natural language processing (NLP) to mine scientific literature and deliver real-time results to researchers.

"We developed this NLP platform as a publicly available app to enable scientists to efficiently discover biological relationships contained in COVID research publications," Holmes says.

The platform:

Contains dictionaries with synonyms to identify things like genes and proteins that may go by various names in scientific literature.
Produces data visualizations of relationships among various biological functions.
Summarizes the most important data points on a given topic from an array of publications.
Depends on data architecture to automate how data is retrieved and processed.

In agricultural biotech, the platform enables researchers to sift through literature to dig up data about plant genetics, Holmes says. The lack of gene-naming standards in the world of plants complicates efforts to search data about plant genetics, she says.

Angela Holmes is the COO of MDS. Photo via mercuryds.com

The platform's ability to easily ferret out information about plant genetics "allows companies seeking gene-editing targets to make crops more nutritious and more sustainable as the climate changes to have a rapid way to de-risk their genomic analyses by quickly assessing what is already known versus what is unknown," Holmes says.

The platform allowed one of Mercury Data Science's agricultural biotech customers to comb through scientific literature about plant genetics to support targeted gene editing in a bid to improve crop yields.

In the field of cancer therapeutics and other areas of pharmaceuticals, the platform helps prioritize drug candidates, Holmes says. One of Mercury Data Science's customers used the platform to extract data from about 2 terabytes (or 2 trillion bytes) of information to evaluate drug candidates. The information included drug studies, clinical trials, and patents. Armed with that data, Mercury Data Science's cancer therapy client signed agreements with new pharmaceutical partners.

The platform also applies to the hunt for biomarkers in neuroscience, including disorders such as depression, anxiety, autism and multiple sclerosis. Data delivered through the platform helps bring new neurobehavioral therapeutics to market, Holmes says.

"An NLP platform to automatically process newly published literature for more insight on the search for digital biomarkers represents a great opportunity to accelerate research in this area," she says.

Mercury Data Science has experience in the field of digital biomarkers, including work for one customer to develop a voice and video platform to improve insights into patients with depression and anxiety in order to improve treatment of those conditions.

The new platform — initially developed as a tool to combat COVID-19 — falls under the startup's vast umbrella of artificial intelligence and data science. Founded in 2017, Mercury Data Science emerged because portfolio companies of the Houston-based Mercury Fund were seeking to get a better handle on AI and data science.

Last April, Angela Wilkins, founder, co-CEO and chief technology officer of Mercury Data Science, left the company to lead Rice University's Ken Kennedy Institute. Dan Watkins, co-founder and managing director of the Mercury Fund, remains at Mercury Data Science as CEO.

The Ken Kennedy Institute fosters collaborations in computing and data. Wilkins replaced Jan Odegard as executive director of the institute. Odegard now is senior director of industry and academic partnerships at The Ion, the Rice-led innovation hub.

Wilkins "is an academic at heart with considerable experience working with faculty and students, and an entrepreneur who has helped build a successful technology company," Lydia Kavraki, director of the Ken Kennedy Institute, said in a news release announcing Wilkins' new role. "Over her career, Angela has worked on data and computing problems in a number of disciplines, including engineering, life sciences, health care, agriculture, policy, technology, and energy."

In honor of International Women's Day on Sunday, here are three female Houston innovators to know this week. Courtesy photos

3 female Houston innovators to know this week

Who's who

In honor of International Women's Day yesterday, today's roundup of Houston innovators features three of the city's entrepreneurs.

From a French ex-pat eliminating cellulite and promoting lymphatic health to a data scientist with a growing company, here are Houston's leading ladies to keep an eye on.

Reda Hicks, founder of GotSpot Inc.

Reda Hicks created GotSpot — a digital tool that helps connect people with commercial space with people who need it. Courtesy of GotSpot

Reda Hicks is a female founder — but more importantly, she supports her fellow female founders. In a lot of ways, its another one of Hicks' side hustles.

This year for SXSW, Hicks, founder of GotSpot — a temporary space finding tool, teamed up with Denise Hamilton, founder of WatchHerWork — a professional women's resource, to create an activation at the festival on March 12 called Texas Female Founders Day, which will feature female founder-focused programming. Despite SXSW being canceled, Texas Female Founders Day will continue.

"The two of us had been to SXSW together for the past two years, and we just saw a whole where a lot of female founders were being lost," Hicks says on this week's episode of the Houston Innovators Podcast. "We can solve both of those problems by creating an experience where it's an entire day that doesn't cost attendees anything and put together a lot of different content that would be really helpful for women growing their business."

Click here to read more.

Angela Wilkins, CTO and co-CEO of Mercury Data Science

It's all a numbers game, and Angela Wilkins of Mercury Data Science is about setting up startups for success. Photo courtesy of MDS

Mercury Fund realized the power of equipping its portfolio companies with data science and artificial intelligence, and the Houston VC fund's first move was to tap data scientist Angela Wilkins to help. The efforts expanded outside Mercury's portfolio, to companies that ranged from early seed stage startups to companies that had raised over $100 million — and they wanted Wilkins' help, either with the basics of data science or execution of analytics.

"In fact, many of the more established companies were sitting on data assets with plans to build AI-enabled products but didn't have the time or people to really start that process," Wilkins says. "After helping a few companies, we realized the need was pretty deep, and bigger than the Mercury Fund portfolio."

Click here to read more.

Emeline Kuhner-Stout, founder of Élastique Athletics

Emeline Kuhner-Stout, founder of Élastique Athletics, wanted to create a product that was easy to wear and benefitted lymphatic health. Photo courtesy of Élastique Athletics

When Emeline Kuhner-Stout was new to Houston, she was a new mom and the only times she had for herself were her daily trips to the gym, and she wanted to make it worth her while.

"There were so many more things I wanted to do for myself, and I just didn't have the time," Kuhner-Stout tells InnovationMap. "It would be so much more efficient if there was a way to combine [elements] to make products that would perform for us."

She got to thinking about creating a product that promoted lymphatic health while being stylish and wearable, so she created Élastique Athletics.

Click here to read more.

It's all a numbers game, and Mercury Data Science is about setting up startups for success. Getty Images

Data-focused Houston company arms startups with the AI tools they need to grow

numbers game

While some say a picture is worth a thousand words, having the right data can be make or break. Houston-based Mercury Data Science is using data and artificial intelligence to paint some really specific pictures for its clients.

MDS was born out of a need for Houston-based Mercury Fund's portfolio companies that wanted a firmer handle on artificial intelligence and data science.

"Three years ago, a number of Mercury Fund portfolio companies and potential investments began to have increasingly important data science and AI components," says Dan Watkins, co-founder and managing director of Mercury Fund. "Mercury's partners wanted a deeper understanding of AI, to understand how the cutting edge meets industry use cases."

Mercury Fund's first move was to tap data scientist Angela Wilkins to lead some training, which then turned into even more workshops and advising. The companies ranged from early seed stage startups to companies that had raised over $100 million — and they wanted Wilkins' help, either with the basics of data science or execution of analytics.

Wilkins, who serves the company as CTO and co-CEO with Watkins, has seen her efforts grow MDS client base. InnovationMap sat down with Wilkins to see how far MDS has come — and where it's going.

InnovationMap: What sort of problems and data solutions are you providing clients?

Angela Wilkins: We love projects that have a direct impact on human health. In health, we build machine learning driven products to create new forms of digital diagnostics to help improve diagnosis in areas like cognitive functioning and depression. We have helped several therapeutics companies accelerate drug discovery and development by extracting insights from biological and imaging data. We have internal tools that use natural language processing to extract knowledge from millions of scientific publications and patents.

We have also worked quite a bit in consumer behavior and some of our physics-oriented data scientists are now working on noise reduction in geophysics technologies.

IM: What feedback do you get from clients?

AW: Company leaders in every sector are feeling the pressure to gain the advantages of AI or risk falling behind. There are many expert level teams available to Fortune 500 organizations. We are one of the very few teams that is entrepreneurial and agile enough to work with earlier stage, high growth organizations.

IM: How does MDS work with Mercury Fund? Has that relationship evolved over the years?

AW: We continue to work with the Mercury Fund portfolio companies but that is a smaller part of what we do. We are venture backed ourselves, and have now become a Mercury Fund portfolio company, with the same growth ambitions as all venture backed companies.

IM: Recently, MDS has seen some growth. How many employees have you added and are you still hiring?

AW: We are up to 20 employees, mostly data scientists, many with 5 to 8 years of experience working in AI, bioinformatics, and data science to provide insights and build products. We are always looking for great data scientists and data engineers to join our team. We also started a fellowship position for recent graduates, and so we can identify and train the next generation of data scientists

IM: What's been the biggest surprise for you as MDS has grown?

AW: We have been able to create this unique culture that thrives on diversity of thought and background. Half of our team is women. We are solving hard problems that benefit from the creativity you get from a wide variety of views.

IM: Where are MDS clients based?

AW: We have clients from San Francisco to Basel. We have learned how to build an integrated, high communication team with the client, so location is not critical.

That being said, we are active in and committed contributors to the Houston innovation ecosystem. Many of us are from a computational biology and bioinformatics background with deep roots in the Texas Medical Center institutions. Houston has amazing talent and we want to show the data scientists that they don't have to leave Houston to work on interesting problems and continue to build skills at the cutting edge while working for companies all over the world.

IM: What sort of trends are you seeing in venture capital? Are these trends happening in Houston?

We are seeing increasing investments in health AI. Fierce Healthcare reports that health AI topped all other sectors last year with $4B invested into AI startups. Andreesen Horowitz has announced their third and largest biotech and health care fund with $750 million to invest: "Machine learning and artificial intelligence [will] have an outsize impact on how we discover drugs and diagnose disease."

We see similar trends in other areas from industrial software to financial services. The upshot is that the adoption of AI creates significant opportunities for startups and significant challenges for larger companies that are not entrepreneurial and able to build their own data science skill set.

As far as Houston goes, the same trends are there but we tend to lag the major technology hubs in adoption. Efforts like TMC Innovation, Station, Rice University/The Ion and Houston Exponential are having a big impact on both the number and pace of startups and, increasingly, those have AI as a key part of their technology stack.

IM: We've talked about how MDS flies under the radar — why do you think that is? Do you think that'll change as you grow?

AW: Our initial focus was on the work for our clients and on building our team. We are ready to be noticed. Thank you for helping us tell the story with this article.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

These are the events to attend each day during the Houston Tech Rodeo 2021

where to be

For the second year, Houston Exponential has tapped into the Houston innovation ecosystem to coordinate a week of events to speak to the city's startups, investors, and startup development organizations.

Houston Tech Rodeo will feature over 160 events between May 16 to 23 both online and all across town. From panels and meetups to office hours and pitch events, there's a lot to navigate in the second annual week. For a complete list of Tech Rodeo events (most of which are free), head to the website.

Here are the events you should make sure not to miss. (InnovationMap is a partner for the event.)

Note: You must register for HTR to be able to register for each event. For that reason, the event pages aren't linked directly. Find the information for each event through the HTR event website under the agenda tab, then sort by the day to find the specific event.

Monday: Gettin' in the Game with Master P: A Fireside Chat

The second annual Houston Tech Rodeo kicks off with hip-hop mogul, actor, producer, entrepreneur, and philanthropist, Percy (Master P) Miller on Monday, May 17, at 8 pm. "Gettin' In the Game with Master P" will be an exclusive fireside chat with the legend himself, interviewed by A-List Angels author and former Forbes editor, Zack O'Malley Greenburg. Hear about Master P's journey going from an international rap artist to a CEO, avid investor, and founder of Nemesis RR-- adding diversity in the automotive industry and empowering a culture of dreamers.